Literature DB >> 7205449

Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care.

S Roy, W M Murphy, B S Arant.   

Abstract

Crescenteric glomerulonephritis preceded by a streptococcal infection with creatinine clearance CCr of less than 30 ml/minute/1.73 m2 was treated by supportive care plus three months of quintuple therapy (prednisone, azathioprine, cyclophosphamide, dipyridamole, and heparin followed by warfarin) in five children (Group A) or by supportive care alone in five others (Group B). Of the glomeruli examined, 69.8 +/- 11.7% (mean +/- SE) in Group A and 64.4 +/- 10.6% in Group B had crescents which involved 54.0 +/- 10.8% and 60.0 +/- 10.5% of glomerular circumference, respectively. Clinical and histologic findings supported a recent streptococcal infection in every patient. Two patients from Group A had mild proteinuria and normal CCr at 12 months; one died abruptly of pulmonary hemorrhage after maintaining a normal CCr for 25 months. Following a second episode of poststreptococcal acute glomerulonephritis seven months after the first, one patient from Group B had persistent mild proteinuria for 41 months and hypertension through 56 months of follow-up. Nine surviving patients have maintained normal CCr for eight to 60 months (mean 29.5 months). The findings of this study suggest that this quintuple therapy offers no advantage over supportive care in the clinical management and outcome of children with severe crescenteric glomerulonephritis when an antecedent streptococcal infection is confirmed by serologic and histopathologic criteria.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7205449     DOI: 10.1016/s0022-3476(81)80703-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  12 in total

Review 1.  Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis.

Authors:  T Matthew Eison; Bettina H Ault; Deborah P Jones; Russell W Chesney; Robert J Wyatt
Journal:  Pediatr Nephrol       Date:  2010-07-23       Impact factor: 3.714

2.  Garland-pattern postinfectious glomerulonephritis with IgA-dominant deposition.

Authors:  Makoto Kanno; Kenichi Tanaka; Hiroshi Kimura; Kimio Watanabe; Yoshimitsu Hayashi; Koichi Asahi; Masaaki Nakayama; Kensuke Joh; Tsuyoshi Watanabe
Journal:  CEN Case Rep       Date:  2013-07-19

3.  Management of Hematuria in Children.

Authors:  O N Ray Bignall; Bradley P Dixon
Journal:  Curr Treat Options Pediatr       Date:  2018-06-14

4.  Crescentic glomerulonephritis in children.

Authors:  H M Jardim; J Leake; R A Risdon; T M Barratt; M J Dillon
Journal:  Pediatr Nephrol       Date:  1992-05       Impact factor: 3.714

5.  Outcome of severe acute post-streptococcal glomerulonephritis in New Zealand children.

Authors:  William Wong; Maxwell Clarke Morris; Jonathan Zwi
Journal:  Pediatr Nephrol       Date:  2008-12-19       Impact factor: 3.714

6.  Clinical spectrum and outcome of crescentic glomerulonephritis in children in developing countries.

Authors:  Deepak Dewan; Sanjeev Gulati; Raj K Sharma; Narayan Prasad; Manoj Jain; Amit Gupta; Alok Kumar
Journal:  Pediatr Nephrol       Date:  2007-12-11       Impact factor: 3.714

7.  Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in children.

Authors:  M C Nash; C L Jones; R G Walker; H R Powell
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

8.  Acute noncrescentic poststreptococcal glomerulonephritis presenting with pulmonary hemorrhage.

Authors:  N Gilboa; S McIntire; L Hopp; D Ellis
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

Review 9.  The treatment of glomerulonephritis in children.

Authors:  G B Haycock
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

Review 10.  Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis.

Authors:  Anjali A Satoskar; Samir V Parikh; Tibor Nadasdy
Journal:  Nat Rev Nephrol       Date:  2019-08-09       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.